<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> is a hallmark of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and is associated with a metabolic and cardiovascular cluster of disorders (<z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0001513'>obesity</z:hpo> [especially visceral], <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo>, <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e>), each of which is an independent risk factor for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Multiple prospective studies have documented an association between <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and accelerated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, as well as in non-diabetic individuals </plain></SENT>
<SENT sid="2" pm="."><plain>The molecular causes of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, i.e. impaired insulin signalling through the phosphoinositol-3 kinase pathway with intact signalling through the <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinase pathway, are responsible for the impairment in insulin-stimulated <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism and contribute to the accelerated rate of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients </plain></SENT>
<SENT sid="3" pm="."><plain>The current epidemic of <z:mp ids='MP_0002055'>diabetes</z:mp> is being driven by the <z:hpo ids='HP_0001513'>obesity</z:hpo> epidemic, which represents a state of tissue fat overload </plain></SENT>
<SENT sid="4" pm="."><plain>Accumulation of toxic <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolites (<z:chebi fb="0" ids="37554">fatty acyl CoA</z:chebi>, diacylglycerol, <z:chebi fb="7" ids="17761">ceramide</z:chebi>) in muscle, liver, adipocytes, beta cells and arterial tissues contributes to <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, <z:hpo ids='HP_0006279'>beta cell dysfunction</z:hpo> and <z:hpo ids='HP_0004943'>accelerated atherosclerosis</z:hpo>, respectively, in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment with <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> mobilises fat out of tissues, leading to enhanced insulin sensitivity, improved beta cell function and decreased atherogenesis </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> and lipotoxicity represent the missing links (beyond the classical <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e>) that help explain the accelerated rate of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> in type 2 diabetic patients </plain></SENT>
</text></document>